Malignes Melanom
Reference16 articles.
1. Bello DM, Faries MB: The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes). Ann Surg Oncol 27(1) (2020) 15–21. 2. Boussios S, Rassy E, Samartzis E et al.: Melanoma of unknown primary: New perspectives for an old story. Crit Rev Oncol Hematol 28;158 (2020) 103208. 3. Bushara O, Tidwell J, Wester JR et al.: The Current State of Neoadjuvant Therapy in Resectable Advanced Stage Melanoma. Cancers (Basel) Jun 26;15 (13) (2023) 3344. 4. Dummer R, Queirolo P, Gerard Duhard P et al.: Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol Jul 14 (2023) S1470–2045 (23) 00334-0. 5. Fay CJ, Jakuboski S, Mclellan B et al.: Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies. Am J Clin Dermatol Jul 3 (2023) doi: 10.1007/s40257-023-00790-8.
|
|